Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Cymbalta Duloxetine hydrochloride Depressive, Major Disorder (MDD) Do not list Complete
Cyramza Ramucirumab Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma Reimburse with clinical criteria and/or conditions Complete
Cyramza Ramucirumab Cancelled
Cystadrops cysteamine Corneal cystine crystal deposits Reimburse with clinical criteria and/or conditions Complete
Daklinza Daclatasvir Hepatitis C, Chronic List with clinical criteria and/or conditions Complete
Daklinza daclatasvir Hepatitis C, Chronic Reimburse with clinical criteria and/or conditions Complete
Darzalex daratumumab Light chain (AL) amyloidosis Reimburse with clinical criteria and/or conditions Complete
Darzalex daratumumab Multiple myeloma, eligible for autologous stem cell transplant Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Darzalex Daratumumab Multiple Myeloma (second-line) Reimburse with clinical criteria and/or conditions Complete
Darzalex Daratumumab Multiple Myeloma Do not reimburse Complete